$FBRX
Forte Biosciences, Inc. Stock $fbrx

$fbrx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024032843 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.451M	$2.814M	$10.62M
YoY Change	66.88%	14.81%	27.97%
% of Gross Profit
Research & Development	$4.353M	$3.567M	$21.86M
YoY Change	-9.07%	43.37%	290.81%
% of Gross Profit
Depreciation & Amortization	$9.000K	$6.000K	$9.000K
YoY Change
% of Gross Profit
Operating Expenses	$7.804M	$6.381M	$32.49M
YoY Change	13.84%	29.2%	133.78%
Operating Profit	-$7.804M		-$32.49M
YoY Change	13.84%		133.78%
Interest Expense		$1.124M	$1.124M
YoY Change
% of Operating Profit
Other Income/Expense, Net	$384.0K	-$615.0K	-$114.0K
YoY Change	276.47%	-1091.94%	-770.59%
Pretax Income	-$7.420M	-$5.872M	-$31.48M
YoY Change	9.88%	20.4%	126.79%
Income Tax
% Of Pretax Income
Net Earnings	-$7.420M	-$5.872M	-$31.48M
YoY Change	9.88%	20.4%	126.79%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.16		-$1.00
Diluted Earnings Per Share	-$0.16	-$0.19	-$1.00
COMMON SHARES
Basic Shares Outstanding	36.39M	36.34M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.44M	$37.13M	$37.13M
YoY Change	-15.2%	-9.67%	-9.67%
Cash & Equivalents	$30.40M	$37.10M	$37.13M
Short-Term Investments
Other Short-Term Assets	$1.058M	$1.202M	$1.202M
YoY Change	186.72%	192.46%	192.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$31.50M	$38.33M	$38.33M
YoY Change	-13.15%	-7.67%	-7.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$106.0K	$109.0K	$109.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$409.0K	$544.0K	$491.0K
YoY Change	-6.41%	11.93%	3.81%
Total Long-Term Assets	$515.0K	$653.0K	$653.0K
YoY Change	17.85%	34.36%	34.36%
TOTAL ASSETS
Total Short-Term Assets	$31.50M	$38.33M	$38.33M
Total Long-Term Assets	$515.0K	$653.0K	$653.0K
Total Assets	$32.02M	$38.98M	$38.98M
YoY Change	-12.78%	-7.18%	-7.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.685M	$1.424M	$1.424M
YoY Change	25.56%	23.5%	23.5%
Accrued Expenses	$1.647M	$2.242M	$2.242M
YoY Change	-31.89%	10.66%	10.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.332M	$3.666M	$3.666M
YoY Change	-11.38%	15.32%	15.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.332M	$3.666M	$3.666M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.332M	$3.666M	$3.666M
YoY Change	-11.38%	15.32%	15.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.9M	-$118.5M
YoY Change	34.22%	36.21%
Common Stock	$154.6M	$153.8M
YoY Change	22.0%	22.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.69M	$35.31M	$35.31M
YoY Change
Total Liabilities & Shareholders Equity	$32.02M	$38.98M	$38.98M
YoY Change	-12.78%	-7.18%	-7.18%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.420M	-$5.872M	-$31.48M
YoY Change	9.88%	20.4%	126.79%
Depreciation, Depletion And Amortization	$9.000K	$6.000K	$9.000K
YoY Change
Cash From Operating Activities	-$6.700M	-$8.969M	-$28.70M
YoY Change	28.85%	210.02%	250.0%
INVESTING ACTIVITIES
Capital Expenditures	$6.000K	$17.00K	$88.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$1.000K	$135.0K
YoY Change
Cash From Investing Activities	-$6.000K	-$16.00K	$47.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-8.000K	-75.00K	24.68M
YoY Change	-233.33%	36.36%	240.89%
NET CHANGE
Cash From Operating Activities	-6.700M	-8.969M	-28.70M
Cash From Investing Activities	-6.000K	-16.00K	47.00K
Cash From Financing Activities	-8.000K	-75.00K	24.68M
Net Change In Cash	-6.681M	-9.060M	-3.975M
YoY Change	28.53%	207.33%	321.08%
FREE CASH FLOW
Cash From Operating Activities	-$6.700M	-$8.969M	-$28.70M
Capital Expenditures	$6.000K	$17.00K	$88.00K
Free Cash Flow	-$6.706M	-$8.986M	-$28.79M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001419041
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38052
CY2023	dei	Entity Registrant Name EntityRegistrantName	FORTE BIOSCIENCES, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1243872
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3060 Pegasus Park Drive, Building 6
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75247
CY2023	dei	City Area Code CityAreaCode	310
CY2023	dei	Local Phone Number LocalPhoneNumber	618-6994
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	FBRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	20400000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36394882
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37125000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41100000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1202000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	411000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	38327000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	41511000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	544000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	486000
CY2023Q4	us-gaap	Assets Assets	38980000
CY2022Q4	us-gaap	Assets Assets	41997000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1424000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1153000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2242000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2026000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3666000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3179000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36335105
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36335105
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21000069
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21000069
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	36000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	153794000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	125841000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118520000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87044000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	35314000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38818000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38980000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41997000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	21862000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5594000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10624000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8302000
CY2023	us-gaap	Operating Expenses OperatingExpenses	32486000
CY2022	us-gaap	Operating Expenses OperatingExpenses	13896000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-32486000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13896000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1124000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	162000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-114000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-145000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31476000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13879000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.8
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.8
CY2023	fbrx	Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingBasic	31571039
CY2023	fbrx	Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingDiluted	31571039
CY2022	fbrx	Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingBasic	17383531
CY2022	fbrx	Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingDiluted	17383531
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31476000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13879000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31472000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13879000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	41548000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	11000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	595000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7122000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4015000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13879000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38818000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	16000
CY2023	fbrx	Common Stock And Pre Funded Warrants Issuance Costs CommonStockAndPreFundedWarrantsIssuanceCosts	272000
CY2023	fbrx	Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Private Investment In Public Equity Pipe Net StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderPrivateInvestmentInPublicEquityPipeNet	24728000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-60000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3284000
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31476000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	35314000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-31476000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13879000
CY2023	us-gaap	Depreciation Depreciation	9000
CY2023	fbrx	Accretion Of Debt Discount On Available For Sale Securities AccretionOfDebtDiscountOnAvailableForSaleSecurities	131000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3284000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4015000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	849000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-258000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	271000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	207000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	186000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1214000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28706000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8185000
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9965000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	10100000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47000
CY2023	fbrx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts	24728000
CY2022	fbrx	Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts	7229000
CY2023	fbrx	Proceeds From Exercise Of Employee Stock Options And Issuance Of Common Stock Under Espp ProceedsFromExerciseOfEmployeeStockOptionsAndIssuanceOfCommonStockUnderEspp	16000
CY2022	fbrx	Proceeds From Exercise Of Employee Stock Options And Issuance Of Common Stock Under Espp ProceedsFromExerciseOfEmployeeStockOptionsAndIssuanceOfCommonStockUnderEspp	12000
CY2023	fbrx	Taxes Paid Related To Net Share Settlement Of Equity Awards TaxesPaidRelatedToNetShareSettlementOfEquityAwards	60000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24684000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7241000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3975000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-944000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41100000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42044000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37125000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41100000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	30000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118500000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28700000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37100000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets, liabilities and expenses include stock-based compensation expense and accruals for clinical trials and drug manufacturing. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	fbrx	Transfers Between Fair Value Hierarchy Levels TransfersBetweenFairValueHierarchyLevels	0
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023Q4	fbrx	Number Of Prefunded Or Common Stock Warrants Exercised NumberOfPrefundedOrCommonStockWarrantsExercised	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3707510
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2529830
CY2023Q4	fbrx	Prepaid Professional Fee PrepaidProfessionalFee	413000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	318000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	341000
CY2023Q4	fbrx	Prepaid Manufacturing And Research Expenses PrepaidManufacturingAndResearchExpenses	306000
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	165000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	70000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1202000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	411000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	118000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109000
CY2023Q4	fbrx	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	280000
CY2022Q4	fbrx	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	473000
CY2023Q4	fbrx	Prepaid Professional Fees Noncurrent PrepaidProfessionalFeesNoncurrent	211000
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	53000
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	13000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	544000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	486000
CY2023Q4	fbrx	Accrued Manufacturing And Clinical Expenses AccruedManufacturingAndClinicalExpenses	1016000
CY2022Q4	fbrx	Accrued Manufacturing And Clinical Expenses AccruedManufacturingAndClinicalExpenses	485000
CY2023Q4	fbrx	Accrued Compensation AccruedCompensation	947000
CY2022Q4	fbrx	Accrued Compensation AccruedCompensation	890000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	276000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	643000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2242000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2026000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25160000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25164000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25160000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25164000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25160000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25164000
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	129000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	19000
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	451000
CY2023Q3	us-gaap	Loss Contingency Lawsuit Filing Date LossContingencyLawsuitFilingDate	August 10, 2023
CY2023Q3	us-gaap	Loss Contingency Name Of Plaintiff LossContingencyNameOfPlaintiff	Camac Fund LP
CY2023Q3	us-gaap	Loss Contingency Name Of Defendant LossContingencyNameOfDefendant	members of the Company’s Board of Directors (the “Directors”) and entities affiliated with certain of the Company’s investors (the “Investors”) and naming the Company as nominal defendant.
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	25000000
CY2023Q4	us-gaap	Loss Contingency Lawsuit Filing Date LossContingencyLawsuitFilingDate	October 28, 2023
CY2023Q4	us-gaap	Loss Contingency Name Of Plaintiff LossContingencyNameOfPlaintiff	Forte Biosciences
CY2023Q4	us-gaap	Loss Contingency Name Of Defendant LossContingencyNameOfDefendant	Camac Fund, LP
CY2023Q4	fbrx	Number Of Prefunded Or Common Stock Warrants Exercised NumberOfPrefundedOrCommonStockWarrantsExercised	0
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16476172
CY2022Q3	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2022-07-21
CY2023Q4	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2024-07-12
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.66
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.91
CY2023	fbrx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock	0.78
CY2022	fbrx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock	1.47
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0231
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M13D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.145
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6875
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2363195
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.29
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M19D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	65000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	345000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.78
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	62917
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.85
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2645278
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2645278
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y2M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	30000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1332746
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.02
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5000
CY2023	fbrx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Closing Stock Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsClosingStockPrice	0.82
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3284000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4015000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4100000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M4D
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6610000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2915000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-79000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6541000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.208
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2628000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.189
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	60000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	370000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.027
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	9000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-4000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	fbrx	Deferred Tax Assets Accrual To Cash Adjustment DeferredTaxAssetsAccrualToCashAdjustment	433000
CY2022Q4	fbrx	Deferred Tax Assets Accrual To Cash Adjustment DeferredTaxAssetsAccrualToCashAdjustment	480000
CY2023Q4	fbrx	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	4508000
CY2022Q4	fbrx	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	2949000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	40000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	40000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1627000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1391000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6515000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6039000
CY2023Q4	fbrx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	4940000
CY2022Q4	fbrx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	978000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	11000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	10000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	528000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	328000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18602000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12215000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18602000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12215000
CY2023	fbrx	Amortization Period Of Domestic Expenses Capitalized AmortizationPeriodOfDomesticExpensesCapitalized	P5Y
CY2023	fbrx	Amortization Period Of Foreign Expenses Capitalized AmortizationPeriodOfForeignExpensesCapitalized	P15Y
CY2023	fbrx	Increase In Deferred Tax Assets Capitalized Research And Development Over Year IncreaseInDeferredTaxAssetsCapitalizedResearchAndDevelopmentOverYear	4000000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6400000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2600000
CY2023	fbrx	Cumulative Change In Ownership Percentage CumulativeChangeInOwnershipPercentage	0.50
CY2023	fbrx	Period For Cumulative Change In Ownership PeriodForCumulativeChangeInOwnership	P3Y
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0

Files In Submission

Name	View Source	Status
0000950170-24-032843-index-headers.html	Edgar Link	pending
0000950170-24-032843-index.html	Edgar Link	pending
0000950170-24-032843.txt	Edgar Link	pending
0000950170-24-032843-xbrl.zip	Edgar Link	pending
fbrx-20231231.htm	Edgar Link	pending
fbrx-20231231.xsd	Edgar Link	pending
fbrx-ex10_16.htm	Edgar Link	pending
fbrx-ex10_17.htm	Edgar Link	pending
fbrx-ex21_1.htm	Edgar Link	pending
fbrx-ex23_1.htm	Edgar Link	pending
fbrx-ex23_2.htm	Edgar Link	pending
fbrx-ex31_1.htm	Edgar Link	pending
fbrx-ex31_2.htm	Edgar Link	pending
fbrx-ex32_1.htm	Edgar Link	pending
fbrx-ex32_2.htm	Edgar Link	pending
fbrx-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
fbrx-20231231_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBRX
Forte Biosciences, Inc. Stock $fbrx

2024 Q1 Form 10-K Financial Statement

#000095017024032843 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBRX Forte Biosciences, Inc. Stock $fbrx

2024 Q1 Form 10-K Financial Statement

#000095017024032843 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBRX
Forte Biosciences, Inc. Stock $fbrx